Royalty Pharma plc
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.4B | $2.3B | $2.4B | $2.2B | $2.3B |
| Research and development | $452.0M | $2.0M | $52.0M | $177.1M | $200.1M |
| Operating income | $1.6B | $1.3B | $1.5B | $307.1M | $1.4B |
| Interest expense | $307.7M | $225.5M | $187.2M | $188.0M | $166.1M |
| Pretax income | $1.3B | $1.3B | $1.7B | $230.1M | $1.2B |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | $770.9M | $859.0M | $1.1B | $42.8M | $619.7M |
| Balance Sheet | |||||
| Cash and equivalents | $618.7M | $929.0M | $477.0M | $1.7B | $1.5B |
| Current assets | $1.5B | $1.8B | $1.3B | $2.6B | $2.9B |
| Total assets | $19.6B | $18.2B | $16.4B | $16.8B | $17.5B |
| Current liabilities | $636.2M | $1.3B | $161.4M | $1.2B | $171.2M |
| Total liabilities | $9.9B | $7.9B | $6.3B | $7.3B | $7.3B |
| Stockholders' equity | $9.7B | $10.3B | $10.1B | $9.5B | $10.2B |
| Cash Flow Statement | |||||
| Cash from operations | $2.5B | $2.8B | $3.0B | $2.1B | $2.0B |
| Depreciation and amortization | $3.9M | $0 | $0 | — | — |
| Stock-based compensation | $289.9M | $2.3M | $2.4M | $2.2M | $2.4M |
| Share repurchases | $1.2B | $229.7M | $304.8M | $0 | $0 |
| Impairments | — | $0 | $0 | $615.8M | $0 |
Shares outstanding 575.8M · Free float 69.8%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.